These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 15792677)

  • 1. Atorvastatin reduces thrombin generation after percutaneous coronary intervention independent of soluble tissue factor.
    Bartok A; Steiner S; Seidinger D; Jetzl A; Huber K; Minar E; Stefenelli T; Kopp CW
    Thromb Res; 2005; 115(6):469-74. PubMed ID: 15792677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients.
    Sanguigni V; Pignatelli P; Lenti L; Ferro D; Bellia A; Carnevale R; Tesauro M; Sorge R; Lauro R; Violi F
    Circulation; 2005 Feb; 111(4):412-9. PubMed ID: 15687128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMG-CoA reductase inhibitors may affect thrombin generation by reducing factor VII activity in hyperlipidemic patients.
    Ural AU; Avcu F
    Thromb Res; 2006; 118(5):665-6. PubMed ID: 16360198
    [No Abstract]   [Full Text] [Related]  

  • 4. Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease.
    Mobarrez F; He S; Bröijersen A; Wiklund B; Antovic A; Antovic J; Egberg N; Jörneskog G; Wallén H
    Thromb Haemost; 2011 Aug; 106(2):344-52. PubMed ID: 21614411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome.
    Chyrchel M; Rakowski T; Rzeszutko L; Legutko J; Dziewierz A; Dubiel JS; Dudek D
    Kardiol Pol; 2006 Dec; 64(12):1357-62; discussion 1363. PubMed ID: 17206539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor.
    Kojima T; Gando S; Kemmotsu O; Mashio H; Goda Y; Kawahigashi H; Watanabe N
    J Cardiothorac Vasc Anesth; 2001 Feb; 15(1):60-4. PubMed ID: 11254842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of long-term testosterone treatment on plasma levels of free TFPI and TF-induced thrombin generation ex vivo in elderly men with low testosterone levels.
    Agledahl I; Brodin E; Svartberg J; Hansen JB
    Thromb Haemost; 2009 Nov; 102(5):945-50. PubMed ID: 19888533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
    Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
    J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy.
    Patti G; Chello M; Pasceri V; Colonna D; Nusca A; Miglionico M; D'Ambrosio A; Covino E; Di Sciascio G
    J Am Coll Cardiol; 2006 Oct; 48(8):1560-6. PubMed ID: 17045888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial.
    Leone AM; Rutella S; Giannico MB; Perfetti M; Zaccone V; Brugaletta S; Garramone B; Niccoli G; Porto I; Liuzzo G; Biasucci LM; Bellesi S; Galiuto L; Leone G; Rebuzzi AG; Crea F
    Int J Cardiol; 2008 Nov; 130(3):457-62. PubMed ID: 18667247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.
    Patti G; Pasceri V; Colonna G; Miglionico M; Fischetti D; Sardella G; Montinaro A; Di Sciascio G
    J Am Coll Cardiol; 2007 Mar; 49(12):1272-8. PubMed ID: 17394957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes.
    Mitsios JV; Papathanasiou AI; Elisaf M; Goudevenos JA; Tselepis AD
    Platelets; 2005 Aug; 16(5):287-92. PubMed ID: 16011979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma free tissue factor pathway inhibitor (TFPI) levels and TF-induced thrombin generation ex vivo in men with low testosterone levels.
    Agledahl I; Brodin E; Svartberg J; Hansen JB
    Thromb Haemost; 2009 Mar; 101(3):471-7. PubMed ID: 19277407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
    Kuryata OV; Yegorova YV
    Kardiol Pol; 2006 Jan; 64(1):44-8; discussion 49-50. PubMed ID: 16444629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early initiation of low-dose atorvastatin treatment after an acute ST-elevated myocardial infarction, decreases inflammatory process and prevents endothelial injury and activation.
    Stefanadi E; Tousoulis D; Antoniades C; Katsi V; Bosinakou E; Vavuranakis E; Triantafyllou G; Marinou K; Tsioufis C; Papageorgiou N; Latsios G; Stefanadis C
    Int J Cardiol; 2009 Apr; 133(2):266-8. PubMed ID: 18187214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of tissue factor pathway inhibitor in the coronary circulation of patients with acute coronary syndromes.
    Golino P; Ravera A; Ragni M; Cirillo P; Piro O; Chiariello M
    Circulation; 2003 Dec; 108(23):2864-9. PubMed ID: 14656922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of tissue factor pathway inhibitor and anti-beta-2-glycoprotein-I IgG on thrombin generation.
    Lean SY; Ellery P; Ivey L; Thom J; Oostryck R; Leahy M; Baker R; Adams M
    Haematologica; 2006 Oct; 91(10):1360-6. PubMed ID: 17018385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
    Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
    Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.